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ABSTRACT
Acute pancreatitis (AP), an acute inflammatory disorder 
of the exocrine pancreas, is one of the most common 
gastrointestinal diseases encountered in emergency 
departments with no specific treatments. Laboratory- 
based research has formed the cornerstone of endeavours 
to decipher the pathophysiology of AP, because of the 
limitations of such study in human beings. While this has 
provided us with substantial understanding, we cannot 
answer several pressing questions. These are: (a) Why is 
it that only a minority of individuals with gallstones, or 
who drink alcohol excessively, or are exposed to other 
causative factors develop AP? (b) Why do only some 
develop more severe manifestations of AP with necrosis 
and/or organ failure? (c) Why have we been unable to find 
an effective therapeutic for AP? This manuscript provides 
a state- of- the- art review of our current understanding 
of the pathophysiology of AP providing insights into the 
unanswered clinical questions. We describe multiple 
protective factors operating in most people, and multiple 
stressors that in a minority induce AP, independently or 
together, via amplification loops. We present testable 
hypotheses aimed at halting progression of severity for 
the development of effective treatments for this common 
unpredictable disease.
INTRODUCTION
Acute pancreatitis (AP) is a leading cause for emer-
gency hospital admission globally. While often self- 
limiting, 20% of patients with AP progress to a more 
severe form with organ failure1 and mortality between 
15% and 35%.2 In the absence of specific treatment, 
current management centres around early fluid resus-
citation, pain control and nutrition.3
There is general consensus that human AP can be 
defined by at least two of three criteria: (1) character-
istic abdominal pain; (2) serum amylase and/or lipase 
levels three or more times the upper limit of normal 
and (3) characteristic abdominal imaging findings.4 
Much research has been undertaken to decipher the 
mechanisms underlying the pathogenesis of AP. Most 
of this has used animal models,5 largely because of 
the limitations of pathophysiological studies of AP in 
human beings. Moreover, our lack of understanding of 
the natural history of AP5 and the relative inaccessibility 
of pancreatic tissue in patients with AP have resulted in 
an incomplete understanding of AP pathogenesis. We 
do not know if the many variations5 between human 
and experimental animals account for the failure of 
clinical trials testing agents effective in animal models 
of AP. Unlike in experimental AP, clinical trials have 
initiated treatments up to 72 hours after admission,6 
but efficacy is likely to require earlier administration.
We aim to provide a state- of- the- art, up- to- date 
review of current understanding of the pathophys-
iology of AP, proposing ways to address unanswered 
clinical questions. We describe how the balance of 
protective factors is disrupted by factors that induce 
AP in a minority of individuals, stressors that act inde-
pendently or together, including via amplification 
loops. Two critical thresholds in the development of 
AP are proposed: threshold 1 is exceeded at the onset 
of AP and threshold 2 is exceeded at the onset of 
severe AP with persistent organ failure (hereon ‘severe’ 
AP describes AP with organ failure for ≥48 hours, 
whether using the Revised Atlanta7 or Determinant- 
Based8 Classifications, see figure 1). We present test-
able hypotheses and a framework for future research 
to develop effective therapeutics to ameliorate and 
prevent this unpredictable disorder.
THE PATHOBIOLOGY OF EXPERIMENTAL AP
We posit that exposure of the pancreas to factors asso-
ciated with AP does not usually lead to AP because 
of adaptive and protective mechanisms in place or 
deployed in response to stressors. When adaptive and 
protective mechanisms are overwhelmed, AP ensues, 
and severity is accelerated by feed forward and ampli-
fication pathways that interact stochastically (see 
figure 2). Many factors may contribute, including toxic 
fatty acids locally,9 and mesenteric lymph components 
systemically.10
Disruption of acinar cell homeostasis
Premature digestive enzyme activation
The pancreatic acinar cell is the functional unit of the 
exocrine pancreas that undertakes highly regulated 
synthesis, storage and secretion of digestive enzymes.11 
These zymogens are packaged as proenzymes in secre-
tory granules, separated from lysosomal hydrolases, 
which would otherwise induce intracellular zymogen 
activation. Numerous further mechanisms within the 
acinar cell and interstitium, including α1- antitrypsin, 
α1- macroglobulin, α1- intertrypsin, protease- activated 
receptor 2,12 and pancreatic secretory trypsin inhib-
itor13 protect the cell from zymogen activation and 
AP. Experimental evidence has confirmed that the first 
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changes following application of noxious stimuli include a block in 
zymogen secretion from progressive disassembly of microtubules 
and actin filaments,14 and premature activation of trypsinogen to 
trypsin15 from colocalisation of trypsinogen with lysosomal enzymes 
such as cathepsin B within fragile vacuoles,16 damaging the acinar 
cell.
Intracellular calcium overload
Excessive intracellular Ca2+ concentrations within the cytosolic 
([Ca2+]i) and mitochondrial ([Ca
2+]m) compartments induced by 
toxins are critical in premature digestive enzyme activation during 
human and murine acinar cell injury and experimental AP.17 The 
central role of physiological Ca2+ signalling in the synthesis and 
secretion of pancreatic zymogens, reviewed elsewhere,18 leaves the 
pancreas vulnerable to disordered Ca2+ signalling induced by toxins 
that cause AP. One breakthrough has been unravelling disordered 
acinar cell Ca2+ signalling in AP pathogenesis, offering new avenues 
for therapy.19–21 Ca2+ stored in the endoplasmic reticulum (ER) is 
released into the cytosol and mitochondria via inositol trisphosphate 
receptor and ryanodine receptor Ca2+ release channels, normally 
elicited by cholecystokinin and/or acetylcholine secretagogue stim-
ulation. Ca2+ release is excessive following exposure to pancreatitis 
toxins, including bile acids, fatty acid ethyl esters, fatty acids and 
hormonal hyperstimulants.21 Unsaturated fatty acids (eg, linoleic, 
linolenic and oleic) result in higher Ca2+ release than saturated 
fatty acids (eg, palmitic and stearic), increase cytoplasmic leakage of 
lactate dehydrogenase and cytochrome C, upregulate inflammatory 
mediators and inhibit mitochondrial complexes I and V, causing a 
drop in ATP levels to induce necrosis.9 22 In response to decreased 
ER Ca2+ concentrations, punctate ER–plasma membrane connec-
tions form from stromal interaction molecule, Ca2+ release- activated 
Ca2+ channel protein 1 (Orai1) and transient receptor potential 
cation channel complexes, to replenish stores from the cell exte-
rior.23 Continued toxic stimulation sustains ER Ca2+ release and 
cellular Ca2+ entry, overloading mitochondria via the Ca2+ uniporter 
and triggering high conductance opening of the mitochondrial 
permeability transition pore (MPTP).17 Hydrogen ions enter the 
mitochondrial matrix through the MPTP with loss of the electro-
chemical gradient required for ATP production.17 Decreased ATP 
impairs Ca2+ clearance by plasma membrane Ca2+ ATPase (PMCA) 
and sarco/ER Ca2+- ATPase pumps, exacerbating [Ca2+]i and [Ca
2+]m 
elevations.17
Sustained overload of [Ca2+]i and [Ca
2+]m is also induced by 
high pressure and Piezo1- mediated Ca2+ entry of sufficient magni-
tude and/or duration to prompt transient receptor potential vanil-
loid type 4 (TRPV4) channel Ca2+ entry.20 ATP production is 
again impaired and autophagy, secretion and endolysosomal traf-
ficking disrupted; activated zymogens are dispersed in the cytosol; 
calcineurin, nuclear factor of activated T cells (NFAT) and the 
Nucleotide- binding oligomerisation domain, Leucine rich Repeat 
and Pyrin domain containing (NLRP)3 inflammasome are acti-
vated; inflammatory cytokines are released; reactive oxygen species 
accumulate, initiating apoptosis; with deficient ATP, necrosis super-
venes; and multiple damage- associated molecular patterns (DAMPs) 
enter the interstitium, lymphatic, portal and systemic circulations, 
driving immune responses that exacerbate pancreatic and systemic 
injury.10 17 20
Variable threshold of injury
There is mounting evidence to suggest that repeated exposure to 
stressors results in adaptive, protective responses but that AP occurs 
when these are inhibited or overwhelmed.24 In animal models, 
cigarette smoking inhibits the protective unfolded protein response 
(UPR) and the transcription factor X- box binding protein 1 (XBP-1) 
generated by ethanol exposure, resulting in ER stress and necrosis 
not observed with either alcohol or smoking alone.24 Moreover, 
pharmacologic or genetic inhibition of XBP- 1s leads to acinar cell 
damage, disordered autophagy and AP.24 Thus, when the normally 
protective UPR, upregulated by cellular stresses, is inhibited or over-
whelmed, pathologic responses ensue.24
Figure 1 Critical thresholds in the balance between protective factors and stressors that determine the onset of clinically apparent AP and 
progression to severe AP, increasing the risk of death. Amplification loops, for example, diminished ATP supply leading to necrosis and necrosis leading 
to inflammation, increase the likelihood of an individual exceeding critical threshold 1 (AP) and critical threshold 2 (severe AP). Effective interventions 
(treatment) will reduce the impact of stressors on the onset and progression of AP and reduce the likelihood to exceeding either threshold. AP, acute 
pancreatitis.
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The inflammatory cascade
Parenchymal and leucocyte pathways
Nuclear factor kappa B (NF-κB) is activated by acinar cell injury25 
independently of trypsinogen,26 triggering transcription of key pron-
flammatory mediators that recruit leucocytes into the pancreas and 
distant organs. NF-κB is comprised of homodimers and heterodi-
mers of the Rel family that exert multiple, often conflicting, effects 
varying between acinar and myeloid cells. The NF- kB homodimer 
RelA/p50, rapidly induced on pancreatic injury, contributes to reso-
lution of inflammation.27 Acinar RelA/p65 also protects against 
chronic inflammation,28 whereas myeloid RelA/p65 promotes 
fibrogenesis characteristic of chronic pancreatitis (CP). Several 
mechanisms are common to parenchymal and immune cells: cyto-
solic Ca2+ elevations activate calcineurin and NFAT,29 driving 
cytokine production and release; the NLRP inflammasome system 
is activated, coordinating immune responses, notably interleukin 
release.30 Tumour necrosis factor alpha (TNFα) is central, produced 
by injured parenchymal cells, resident macrophages and infiltrating 
leucocytes. Through chemotactic cytokine leucocyte (CCL) and 
chemokine receptor interactions, for example, CCL2/chemotactic 
cytokine receptor-2, monocytes are recruited and differentiate into 
TNFα-activated macrophages. Neutrophils are among the first 
immune cells recruited into the pancreas and lung, demonstrated 
by cellular, chemokine and adhesion molecule blockade studies.31 
Neutrophils activate trypsinogen in acinar cells32 as do trypsinogen 
in endocytosing macrophages, contributing to AP severity.33 These 
cells amplify the inflammatory cascade, generating many chemok-
ines and cytokines including interleukins 1 and 6 (IL-1 and IL-6), 
and intercellular adhesion molecule 1 (ICAM-1) to promote pancre-
atic and extrapancreatic multiorgan injury. Recent results, together 
with findings made from other forms of organ injury, suggest signif-
icant interactions between innate and adaptive immune responses.30 
NF-κB activation in myeloid cells and expression of IL6 by macro-
phages mediatethe development of murine AP34 by binding to its 
membrane receptor (IL6R) or complexing with soluble IL6R, both 
of which activate IL6 signal transducer (glycoprotein 130 (GP130)). 
GP130 activates the Janus kinase 2 to phosphorylate signal trans-
ducer and activator of transcription 3 (STAT3) at Y705. In infil-
trating myeloid cells, NF-κB regulates production of IL6 at sites of 
inflammation; the ensuing persistent activation of STAT3 results in 
high levels of CXCL1, which together with ICAM1 in lung endothe-
lial cells mediates granulocyte infiltration into the lung, promoting 
lethal acute lung injury.34 35
Pattern recognition and pattern recognition receptors (PRRs)
DAMPs, for example, histones, high- mobility group box protein 1 
(HMGB1), DNA, ATP, hyaluronic released from acinar cell injury and 
death, are recognised by innate immune cells of the monocyte macro-
phage system to induce further local and systemic inflammation.36 
Figure 2 Amplification loops that contribute to an individual exceeding critical threshold 1 (Acute pancreatitis (AP)) and critical threshold 2 (severe 
AP) in the pathogenesis and progression of AP. While distinct, the loops interact and drive each other. (A) Toxins that increase the open probability of 
inositol trisphosphate receptor (IP3R) and ryanodine receptor (RyR) Ca
2+ channels induce release of Ca2+ from the endoplasmic reticulum (ER), raising 
the concentration of Ca2+ in the cytosol ([Ca2+]i) and mitochondria ([Ca
2+]m) while lowering that in the ER ([Ca
2+]ER), which drives formation of stromal 
interaction molecule−calcium release- activated calcium channel−transient receptor potential canonical cation channel (STIM- ORAI- TRPC) puncta 
for Ca2+ entry. Continued elevation of [Ca2+]m induces the mitochondrial permeability transition pore (MPTP) with loss of mitochondrial membrane 
potential and ATP production, which impairs Ca2+ clearance by the sarcoendoplasmic reticulum and plasma membrane Ca2+ ATPases (SERCA 
and PMCA) pumps, further increasing [Ca2+]i and [Ca
2+]m. (B) Diminished ATP production induces defective autophagy, disordered endolysosomal 
trafficking, building up activated digestive enzymes and further driving intracellular and extracellular injury. (C) Sustained elevations of [Ca2+]i and 
[Ca2+]m induce nuclear factor of activated T cells (NFAT), nuclear factor kappa B (NF-κB) and the Nucleotide- binding oligomerisation domain, Leucine 
rich Repeat and Pyrin domain containing (NLRP) inflammasome system resulting in cytokine release, stimulating resident and infiltrating leucocytes, 
causing further parenchymal injury. (D) Acinar–ductal tango: ductal secretion may be diminished by inherited or acquired defects of cystic fibrosis 
transmembrane conductance regulator (CFTR) function or ductal obstruction that in turn injures acinar cells that release activated zymogens which 
further diminish ductal function. (E) Necrosis releases damage- associated molecular patterns (DAMPs, for example, histones, DNA) that attract 
and activate leucocytes which release cytokines, inflammatory mediators and neuropeptides. Parenchymal and circulating inflammatory mediators 
exacerbate local pancreatic and distant systemic organ injury resulting in further necrosis. (F) Inflammatory injury of the gut, lung and other organs 
damage mucosal and epithelial protective barriers, which bacteria breach to infect local and distant sites. Systemic sepsis impacts on organ function, 
prompting further inflammation and tissue injury.
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Widespread organ injury in severe AP notably of the gastrointestinal 
permeability barrier is associated with infectious complications and 
bacterial products, for example, lipopolysaccharide (LPS), other 
endotoxins and flagellin termed pathogen- associated molecular 
patterns (PAMPs), which also activate the innate immune system.37 
DAMPs and PAMPs ligate a growing array of PRRs, including toll- 
like receptors (TLRs), nucleotide- binding oligomerisation domain- 
like receptors (NLRs and NLRP receptors), C- type lectin receptors 
and sensor stimulator of interferon genes.38 Crosstalk between these 
receptors determines the overall shape of the immune response. It 
is of direct interest that circulating histones, HMGB1 and DNA 
correlate with clinical AP severity.39
Autophagy
Autophagy is the major lysosome- mediated catabolic process by 
which cells eliminate damaged, defective, or unwanted cytoplasmic 
organelles, proteins and lipids, and recycle constituents for energy 
and biogenesis needs.40 Deregulation of autophagy is associated 
with AP pathogenesis.41 Both human and experimental pancreatitis 
display severe defects in acinar cell lysosomal functions with reduced 
enzymatic activities of lysosomal proteases, cathepsins and degrada-
tion of integral lysosome- associated membrane proteins (LAMPs) 
critical to the structure and function of lysosomes. The inhibition 
of autophagy manifests by the accumulation in acinar cells of auto-
phagic vacuoles, filled with poorly degraded material, regarded as an 
early marker of experimental and human AP.
Recent studies have used genetic models to target autophagy/
lysosomal pathways in the maintenance of acinar cell homeostasis 
and initiation of AP. Mice with pancreas- specific knockouts of key 
autophagy mediators autophagy related protein (Atg) 542 or Atg743 
or the transcription factors TFEB and TFE3 that mediate lyso-
somal biogenesis and autophagy,44 and LAMP2 knockout mice,45 
all develop spontaneous AP and subsequent features of CP, with 
trypsinogen activation, fibrosis and acinar- to- ductal metaplasia. 
Collectively, these findings confirm an essential role of autophagy/
lysosomal pathways in maintaining pancreatic acinar cell homeo-
stasis, and strongly implicate their disorders in initiation and devel-
opment of AP.
Ductal bicarbonate (HCO3
−) secretion protects the pancreas
Pancreatic ductal epithelial cells have a prominent role in main-
taining the integrity of the pancreas. They secrete HCO3
−- rich fluid 
into the ductal lumen that prevents premature activation of tryp-
sinogen inside the lumen and washes out digestive enzymes from 
the pancreas. Deficient ductal function changes the composition and 
volume of the fluid, leading to acinar cell damage. In recent years, 
it has been demonstrated that low concentrations of ethanol and 
bile acids stimulate HCO3
− secretion while high concentrations are 
inhibitory46 47 (see table 1). Human studies suggest moderate alcohol 
intake (less than 40 g/day) might be protective and reduce the risk of 
AP, more so in women.48 When the concentration of ethanol or bile 
acids reaches a toxic level, HCO3
− secretion is reduced and irrevers-
ibly elevated intracellular Ca2+ results in mitochondrial damage and 
cell death.49 Ductal fluid secretion is also decreased due to inhibition 
of aquaporin-1 by bile acids.50 Taken together, the impaired ductal 
function contributes to the development of AP (see figure 2).
The acinar–ductal tango
The altered HCO3
− secretion is primarily due to inhibition or muta-
tions of the cystic fibrosis transmembrane conductance regulator 
(CFTR) Cl− channel, which transports HCO3
− into the lumen, 
in close association with solute carrier family 26 (SLC26) anion 
exchanger (Cl−/HCO3
− exchanger). In patients with cystic fibrosis, 
the type of mutation plays a significant role in determining the risk 
of AP. Two cohort studies demonstrated that with mild mutations the 
incidence of AP is much higher.51 52 Ductal obstruction can also lead 
to AP. Pancreatic cancer or bile duct stones can cause obstruction and 
prevent the outflow of pancreatic fluid causing AP.53 On the other 
hand, impairment of acinar cell function induces ductal damage, 
which aggravates the course of AP (figure 3). Intra- acinar or luminal 
trypsinogen activation markedly reduces ductal HCO3
− secretion 
through inhibition of the SLC26 anion exchanger and CFTR Cl− 
channels expressed on the duct cell apical membrane, lowering 
luminal pH. This low pH enhances trypsinogen autoactivation that, 
in a vicious cycle, further reduces HCO3
− secretion54 (see figure 2).
Islet hormones and neuropeptides
Beneficial effects
As there is complex interplay between the endocrine and exocrine 
pancreas,55 notably arterial flow from islets to acini, investigators 
have studied effects of islet hormones on AP. Somatostatin and its 
analogues inhibit basal and stimulated exocrine pancreatic secre-
tion,56 reduce lipid peroxidation, leucocyte infiltration and necrosis 
in experimental AP, and promote tissue organisation and healing. It 
is disappointing that meta- analysis of randomised clinical trials have 
shown that neither somatostatin nor its analogues have efficacy in 
the treatment of clinical AP.57 Insulin, however, protects pancreatic 
acinar cells by facilitating PMCA pump Ca2+ clearance, limiting 
Table 1 Protective factors that prevent acute pancreatitis throughout 
life except when one or more stressors build up, increasing the 
likelihood of acute pancreatitis, which will occur if the critical threshold 
is exceeded
Protective factors Stressors
Systemic toxin protection and clearance 
mechanisms
Genetic variants imposing limits on cell function
Facilitatory metabolic effects of islet 
hormones
High ductal pressure or parenchymal trauma
Separated, discrete acini and parenchymal 
lobules
Toxin exposure to which acinar cells are 
vulnerable
High output secretory units with robust 
acinar cells
Reduced O2 supply for oxidative phosphorylation
Ca2+ supply ducted within the endoplasmic 
reticulum
Untimely and/or excessive stimulation of secretion
Prompt unfolded protein response on cellular 
stresses
Impaired ductal function and zymogen clearance
Transcription/release of danger signals 
suppressed
Prolonged opening of inositol trisphosphate 
receptor and ryanodine receptor Ca2+ channels
Highly active acinar cells with abundant 
functional mitochondria
Sustained Ca2+ entry via calcium release- activated 
calcium channel, transient receptor potential 
canonical cation channel, transient receptor 
potential vanilloid
Sufficient ATP for energy- dependent functions High conductance opening of mitochondrial 
permeability transition pore with loss of ∆ΨM
Stimulus–secretion and stimulus–metabolism 
coupling
Diminished oxidative phosphorylation and ATP 
supply
Proper zymogen synthesis that prevents 
intracellular activation
Zymogen and lysosomal–protease colocalisation
Zymogens packaged in exclusive subcellular 
compartments condensed with enzyme 
inhibitors
Defective autophagy and endolysosomal cycling
Flow away with ductal secretion at high pH Build- up of activated digestive enzymes within 
acinar cells
Enhanced ductal flow with low doses of 
toxins
Activation of nuclear factor of activated T cells, 
nuclear factor kappa B, Nucleotide- binding 
oligomerisation domain, Leucine rich Repeat and 
Pyrin domain containing signalling
Zymogens activated distantly in duodenum 
with enterokinase
Stellate and resident macrophage danger 
responses
  Infiltration of activated innate immune cells
  Necroinflammatory amplification loops
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Ca2+ overload and consequent cellular injury, likely increasing 
nutrient supply for ATP production.58 While these findings require 
confirmation in vivo, early phase trials assessing the hyperinsuli-
naemic euglycemic clamp technique can be envisaged, if justified by 
accumulating preclinical data.
Deleterious effects
Neuropeptides and neuroinflammation have been a focus in AP 
research for many years,59 60 also pursued avidly in brain research 
(there are now several thousand neuropeptides identified); earlier 
AP work investigated the kinin–kallikrein system,59 later substance 
P60 and galanin.61 Kinins are derived from kininogens that modu-
late blood pressure, vascular permeability and pain transmission 
through the bradykinin receptor. Seminal work 60 years ago iden-
tified a key role for bradykinin in hypotension, pancreatic oedema, 
fluid shifts and haemoconcentration in AP,59 leading to early trials 
of trasylol. Unfortunately, preclinical efficacy was not confirmed 
to confer clinical benefit.57 Substance P, a prototypical tachykinin, 
contributes to AP through neurogenic inflammation,62 mediated via 
neurokinin-1 (NK1) receptors60 present in acinar cells upregulated 
in AP.60 Substance P increases vascular permeability and interstitial 
oedema,60 potentiates effects of other secretagogues,63 upregulates 
production of proinflammatory mediators, and increases NF-κB 
activation,64 pancreatic myeloperoxidase activity and necrosis in 
experimental AP.65 Galanin, another neuropeptide ubiquitously 
present in the nervous system, contributes to AP,61 potentiating 
effects of other secretagogues,66 promoting neuroinflammation,65 
reducing pancreatic microcirculation, enhancing neutrophil func-
tion67 and inhibiting ductal HCO3
− secretion.68 Neuropeptides and 
neuroinflammation contribute to pain in AP, implicating bradykinin 
and TRPV1.62
Genetic mutations increasing the susceptibility to AP
Variations in several genes in many populations have been linked to 
increased susceptibility to CP, which may be heralded by a sentinel 
attack of AP. Genetic mutations affect different processes and path-
ways, including trypsin activation (PRSS1, serine protease inhibitor 
Kazal type 1 (SPINK1) and chymotrypsin C (CTRC)),69 chloride 
and HCO3
− transport (CFTR),70 protein misfolding response 
(carboxypeptidase A1, CPA1),71 and Ca2+ signalling (TRPV6)72 
and suggest a shared pathobiology between AP and CP. Variations 
in the claudin 2 gene (CLDN2) alter the inflammatory response to 
acinar cell destruction and fibrosis.73 The inheritance varies from 
autosomal dominant for PRSS1, autosomal recessive for CFTR, to 
complex and sporadic inheritance patterns for other genes. Apte et 
al 74 suggested that investigation into protective mechanisms associ-
ated with CFTR mutations may uncover pancreatic susceptibility to 
alcohol toxicity. Maléth et al47 provided clinical evidence of lower 
levels of CFTR messenger RNA and protein expression in pancre-
atic tissue in patients with AP compared with healthy volunteers 
and evidence that alcohol and fatty acids inhibit CFTR activity and 
fluid and bicarbonate secretion in pancreatic ductal epithelial cells. 
In patient populations, variations in CFTR and SPINK1 are the most 
frequently detected. Other than an earlier age at presentations, clin-
ical features in patients with genetic mutations are similar to those 
without.75 Koziel et al76 found mutations in SPINK1 (especially 
p.N34S) predispose individuals to AP, especially with alcohol abuse, 
and promote more severe disease. Polonikov et al77 confirmed a 
robust association of polymorphism rs10273639 at PRSS1−PRSS2 
with AP modified by alcohol consumption. Since AP, recurrent AP 
and CP represent a disease continuum,78 it is reasonable to conclude 
that variations in the described genes play a role in AP pathogen-
esis. A recent meta- analysis observed significant risk of AP with 
SPINK1 variants; the lack of association with PRSS1 was attributed 
to exclusion of paediatric populations, and few data were available 
for CFTR and CTRC variants.79 Interestingly, the meta- analysis also 
identified an increased risk of AP related to variation in genes linked 
to IL- 1B and IL-6 cytokine production.79 Genome- wide association 
studies have identified CLDN2 and PRSS1−PRSS2 variants altering 
the risk of alcohol- related and sporadic pancreatitis.73 It is, thus, 
plausible that AP due to different risk factors might have a distinct 
genetic background making the interpretation of genetic results 
difficult (as cohorts in the subgroups are small and phenotypes not 
well characterised). These associations need replication and must be 
reported currently with caution, including data on IL6 and other 
immune genes.
Pancreatic stellate cells in necroinflammatory amplification
Stellate cells are resident pancreatic cells next to acinar cells. The 
teams of Apte and Bachem80 81 first identified stellate cells and their 
role in pancreatic pathophysiology. Evidence has emerged to support 
the existence of a ‘necrotic amplification loop’ in AP between acinar 
and stellate cells.82 It has been demonstrated in experimental AP that 
initiation of an inflammatory signal potentiates acinar cell injury, 
further activating inflammatory signals and acinar cytokine/adipo-
kine secretion that amplify the inflammatory response. The resultant 
necrosis in a proportion of acinar cells leads to the release of acti-
vated proteases and bradykinin that act on neighbouring stellate cells 
by evoking Ca2+ signals. Trypsin- induced and bradykinin- induced 
Ca2+ signals within stellate cells, in turn, activate nitric oxide (NO) 
synthase to produce NO. NO diffuses into neighbouring acinar 
and endothelial cells exacerbating parenchymal cellular damage, 
decreasing the pancreatic microcirculation and increasing adherent 
leucocytes in the pancreas.83 This results in a vicious circle termed 
a ‘necrotic amplification loop’82 that intensifies local and systemic 
inflammation in AP. Stellate cells may be activated directly by ethanol 
and its metabolites to secrete proinflammatory84 and fibroinflam-
matory19 signals. Stellate cells express many membrane receptors 
including TLRs85 that can be stimulated by growth factors, cytokines 
and DAMPs released by damaged acinar or immune cells. LPS binds 
to TLRs on stellate cells, activating fibroinflammatory signals medi-
ated by extracellular Ca2+ entry.19 There are high levels of circulating 
LPS in alcohol- fed animals, in alcoholics and patients with AP,86 
likely due to alcohol- induced increases in gut permeability; further-
more, LPS injection induces AP in alcohol- fed animals.74
Figure 3 The acinar–ductal tango depicting the ductal changes 
that precipitate acinar injury and the effect of resultant acinar injury 
on ductal cell dysfunction. CFTR, cystic fibrosis transmembrane 
conductance regulator.
P
rotected by copyright.
 on O
ctober 19, 2020 at U
niversity of S
zeged S
zte E
gyetem
i K
onyvtar.
http://gut.bm
j.com
/
G
ut: first published as 10.1136/gutjnl-2020-322163 on 24 S
eptem
ber 2020. D
ow
nloaded from
 
6 Barreto SG, et al. Gut 2020;0:1–10. doi:10.1136/gutjnl-2020-322163
Recent advances in basic science
Pancreatic stellate cells contribute to reorganisation of the pancre-
atic environment by producing or degrading extracellular matrix 
(ECM) molecules. ECM components (eg, fibronectin, collagen I, 
etc) are critical to multiple physiological and pathological signalling 
pathways including inflammation, tissue damage regulation and 
might provide a scaffold for tissue repair through interaction with 
acinar cell integrin receptors.87 88 In this context, they may influ-
ence the balance between protectors and stressors in determining the 
severity of AP, and the risk of recurrent episodes.
What critical threshold of injury triggers AP?
Some or all above events may unfold when the pancreas is exposed 
to aetiological triggers. Mechanisms deciphered from preclinical 
experiments have clinical parallels, notably disordered Ca2+ signal-
ling within human pancreatic acinar cells and their consequent 
injury, innate immune responses, mediation by DAMPs, PAMPs 
and PRRs, and necroinflammatory amplification.20 Substantial gaps 
remain, as translation is necessarily incomplete. Unlike clinical AP, 
experimental AP is predictable and consistently replicated, although 
with significant differences between species, aetiologies and assess-
ment methods.5 Preclinical models differ from human disease, but 
preclinical investigations remain essential to advance our under-
standing of and therapies for AP, through a translational pipeline. 
While preclinical AP displays a continuum of injury, clinical AP is 
defined by two of the three criteria outlined earlier, after an emer-
gency presentation to hospital or complicating an inpatient stay for 
other reasons. This indicates a critical threshold has been exceeded 
in patients developing clinical AP. While this threshold will typi-
cally have been reached prior to diagnosis, the time of diagnosis is 
preferred to represent when this has occurred, to enable and facil-
itate areas of research. One important area would be more nearly 
complete and rapid diagnosis of all AP globally, for example, from 
the onset of symptoms, essential to improved outcomes.
While Gryshchenko et al suggested AP is characterised pathobio-
logically by injury of ‘a portion of acinar cells’,82 we proposed previ-
ously that AP occurs on injury of a ‘critical mass’ of acinar cells,89 
accurate measurement of which, for example, using activation 
peptides requires further development. Mounting evidence supports 
a balance between protective systems and multiple stressors (see 
table 1); when stressors overwhelm protectors, parenchymal injury 
occurs. If inflammatory signals from injured acinar cells are ampli-
fied by stellate cells, resident macrophages and infiltrating leucocytes, 
with release of neuropeptides and other inflammatory mediators, 
classical clinical features develop, namely, pain, swelling and loss 
of function. In AP, feed forward necroinflammatory amplification 
can be so profound that extensive necrosis and organ failure may 
supervene. Therefore, we propose that an attack of clinically evident 
AP is caused by a critical level of acinar cell injury. This first critical 
threshold is reached when local protective responses are exceeded, 
a nidus of inflammation propagates, and multiple inflammatory 
mediators are released. Feed forward necroinflammatory amplifica-
tion loops increase local pancreatic damage and spill into a systemic 
inflammatory response, which above a second critical threshold 
induces distant organ injury that can be profound (figure 4).
Figure 4 The multifactorial ‘critical threshold’ hypothesis in the causation of AP. AP, acute pancreatitis; Ca2+, free cytosolic calcium; MPTP, 
mitochondrial permeability transition pore; UPR, unfolded protein response.
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IMPLICATIONS FOR CLINICAL AP
Epidemiology and health services research
Much population- based research can address how individuals exceed 
the critical thresholds proposed, which may require analysis of large 
data sets. Basic to this are figures for the incidence of AP, estimated 
at ~35 individuals per 100 000 people/year, with marked variation 
between countries, and mortality of 2%–5%.90 Detailed data on the 
epidemiology of AP outside Europe and North America are required 
to assess global burden, including age, gender, lifestyle, aetiology, 
disease course and outcome. Hospital admission underpins the diag-
nosis of AP, that is, when the first critical threshold can be identified 
to have been exceeded, but the determinants and timing of hospital 
admission are largely undefined, including individual biological and 
psychosocial factors, and the nature, availability and accessibility of 
health service provision.90 Factors affecting access to and quality 
of hospital care are important in addressing health inequalities, 
health service policy and financing globally. AP is the most common 
disease of the pancreas, yet there have been relatively few large- scale 
genomic studies including many patients with typical etiologies,77 79 
unlike for CP. DNA collection and storage from patients with well- 
characterised AP should be a priority to feed into well designed and 
funded consortia studies. The most common cause of AP is gall-
stones followed closely by heavy alcohol consumption, although 
reversed in some countries with notable differences to explore, for 
example, hypertriglyceridaemia in China,91 related to life style and 
increasing in incidence.92 Addressing the aetiology of AP prevents 
future attacks, but much investigation may be left for varying periods 
after onset, when it may be too late to detect for example, high 
triglyceride levels or other aetiologies. Comparative trials of alterna-
tive diagnostic and preventative algorithms would strengthen focus 
on appropriate workup and preventative strategies.
Alcohol consumption is the most common cause of recurrent AP, 
the risk of which can be reduced substantially by abstinence. Fewer 
than 5% of heavy drinkers, however, develop pancreatitis,93 which 
remains largely unexplained. Short- term heavy drinking increases 
the risk of AP. A 52% (RR 1.52, 95% CI: 1.12 to 2.06) increased risk 
of AP has been estimated for every five standard spirit drink incre-
ment consumed on a single occasion.94 More recently, the effects 
of smoking have been noted; smoking ≥1 pack/day is associated 
with recurrent AP (and CP), independent of alcohol.95 Other health- 
related behaviours such as high- fat diets may push individuals over 
the first critical threshold. Animal studies demonstrate that while 
alcohol increases the vulnerability to AP, additional triggers, such as 
cholecystokinin (CCK) administration, are needed to induce AP.96 
CCK is an endogenous hormone stimulated by diets high in fat and 
protein.97 Indeed, high intakes of saturated fat and cholesterol are 
positively associated with the incidence of gallstone AP.98 Studies are 
needed to investigate the short- term and long- term impact of diet on 
the risk of AP, including intake shortly before the onset of AP, when 
two or more factors may cause an individual to exceed the first or 
second critical threshold outlined.
Precision patient management
Despite our seemingly detailed understanding of the pathogenesis 
of AP derived from animal models, we have many unanswered 
questions in human AP, which is significantly more heterogeneous 
and may require substantial omics data to unravel. Figure 5 pres-
ents a multicausal model of AP with interventions to target gaps in 
understanding risk factors and their threshold for disease causation. 
Why does AP develop in some, but not other people exposed to 
known risk factors for AP? How precisely might the risk of AP from 
gallstone passage through the ampulla of Vater be determined, for 
example, number, size, shape, bile constituents, morphology and 
function of the biliary tree, Oddi’s sphincter and exocrine pancreas? 
If accurate determination of risk were possible, might prophylactic 
Figure 5 This hypothesised multicausal model of acute pancreatitis differentiates two main types of causes: behavioural and clinical. Behavioural 
component causes, such as excessive drinking, that are more common in young adults to middle aged people increase the potential for 
pancreatitis (solid black line). People with greater genetic vulnerability (eg, mutations in known genetic susceptibility factors, such as cystic fibrosis 
transmembrane conductance regulator and serine protease inhibitor Kazal) may experience pancreatitis at a lower threshold of drinking (dotted black 
line). Clinical component causes, such as gallstones, increase with age (solid red line). The risk is elevated in women, and in the presence of metabolic 
factors, such as obesity. Among other causes, metabolic factors, such as hypertriglyceridaemia- induced pancreatitis, are seen in individuals with an 
underlying lipid abnormality who have one of more secondary factors, such as diabetes.
P
rotected by copyright.
 on O
ctober 19, 2020 at U
niversity of S
zeged S
zte E
gyetem
i K
onyvtar.
http://gut.bm
j.com
/
G
ut: first published as 10.1136/gutjnl-2020-322163 on 24 S
eptem
ber 2020. D
ow
nloaded from
 
8 Barreto SG, et al. Gut 2020;0:1–10. doi:10.1136/gutjnl-2020-322163
Recent advances in basic science
cholecystectomy be appropriate? We know cholecystectomy for gall-
stones99 and abstinence from smoking and/or alcohol reduce the risk 
of AP. Nevertheless, patients may develop recurrent AP following 
cholecystectomy for presumed gallstone AP.100 What impact has 
an episode of AP on the likelihood of a subsequent episode? How 
does this vary between individuals? Multiple factors including diet, 
quantity and type of alcohol, and pre- existing genetic variants may 
contribute to an episode of AP, each of which alone would not 
necessarily have triggered an episode. This is not uncommon in chil-
dren, especially in those with recurrent AP.101 Obesity contributes 
to an amplified SIRS in AP and is associated with local and systemic 
complications, including mortality.102 How do we determine the 
primary cause to prevent future episodes? Postendoscopic retrograde 
cholangiopancreatography AP has presented a unique opportunity 
to institute and further develop preventative strategies. Fastidious 
patient selection and informed decision- making, prophylactic rectal 
non- steroidal anti- inflammatory drugs, careful guidewire- assisted 
cannulation, pancreatic stent placement and prompt intravenous 
fluid hydration have reduced but not removed the risk of AP,103 
necessitating further trials.
Why do some but not other people with AP develop organ 
dysfunction and exceed the second threshold? Animal studies 
suggests the magnitude of noxious stimuli is key, but clinical quanti-
fication is elusive, as is accurate identification of severity on admis-
sion. Similar questions posed concerning the first critical threshold, 
including multiple cocontributory factors, apply to the second crit-
ical threshold. Despite our knowledge of the clinical course and 
underlying mechanisms of AP, we are unable to prevent its progres-
sion once the disease continuum has set in, treatment for which is 
primarily supportive and directed at complications. Early judicious 
intravenous fluid resuscitation corrects hypovolaemia from third- 
space fluid losses to maintain or restore pancreatic, splanchnic and 
systemic perfusion.99 The optimum fluid type and methods of moni-
toring to avoid overadministration are undetermined, however, and 
why only some patients develop pancreatic necrosis and distant 
organ dysfunction despite being adequately fluid resuscitated 
requires determination. Since a high haematocrit is associated with 
poorer outcome, earlier presentation and earlier fluid resuscitation 
is desirable; this being so, patients should be encouraged to present 
as soon as possible after symptom onset from AP. Lung injury, the 
most common distant organ dysfunction, has multiple potential 
contributors including circulating phospholipase A2, elastase, LPS 
and IL6–IL6R complexes. These pathways have been targeted 
effectively in animal models but clinical trials have failed to match 
expectations thus far, suggesting the need to test new treatments 
more rapidly after diagnosis for example, IL6 antagonists or target 
alternative pathways, for example, the kynurenine mono- oxygenase 
pathway.104 Hyperactive immune responses are probable instru-
ments of injury, so unravelling any contribution of immune response 
gene variants is a priority, and immune targeting may be appro-
priate. A correlated persistent inflammation, immunosuppression 
and catabolism syndrome may contribute to late patient death.105 
It is hoped that the results of the rapid treatment of acute pancre-
atitis with infliximab (RAPID- I) Trial (NCT03684278) testing early 
administration of the TNF-α inhibitor infliximab will be informative 
in this regard. Treatments are required to reduce the early and long- 
term impact of AP, including organ failure, necrotising pancreatitis, 
superadded infection, exocrine and endocrine failure,106 107 recur-
rent AP and CP. The risks of long- term effects are significantly higher 
in alcohol- related AP compared with gallstone- related disease.107 An 
encouraging strategy to prevent AP includes focusing on upregu-
lating preventative pathways, such as reducing ER stress by targeting 
XBP-1 in the acinar cell thereby facilitating a robust UPR to stressors, 
namely alcohol.108
FUTURE DIRECTIONS
We have placed current understanding of the pathogenesis of AP 
into a framework that has two thresholds critical to the develop-
ment and impact of AP on individuals. Our approach is designed 
to assist forward and reverse translation integrating animal and 
human studies to stimulate further clinical studies and trials in the 
prevention and treatment of AP. To date, animal studies have been 
used more to elucidate underlying mechanisms and monitor patho-
physiologic events, less to evaluate clinical interventions and their 
effects. Greater focus is required on appropriate preclinical models 
to develop interventions after disease initiation, as in the clinical 
setting.
We propose the two critical thresholds and associated framework 
to refocus endeavour on improvement of the management and 
outcome of AP: to estimate and reduce risk, assess and modify contrib-
uting cofactors, capture more cases earlier, optimise and personalise 
resuscitation, analgesia, nutrition, aetiological and severity assess-
ment, and develop effective prophylaxis and therapy. A pipeline of 
trials using ORAI inhibitors to reduce Ca2+ injury,109 simvastatin 
to reverse deregulated autophagy110 and agents to prevent MPTP 
opening or pathologic ER stress could confirm an agent that halts 
progression of early pancreatic injury and prevent systemic progres-
sion. Inhibition of inflammatory mediators including TNF-α or IL-6, 
particularly given early, could ameliorate AP even after exceeding 
the second threshold. Omics technologies and novel measurement 
systems offer fertile areas for the development of precision- based 
therapy. These approaches also apply to prevention of iatrogenic 
and recurrent AP. To complement this, population- based studies are 
needed to more accurately determine who develops AP, when and 
why, and to inform health service policy and delivery for those with 
AP.
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